Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share acquisitions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details specific share acquisitions by company leadership on August 11, 2015, executed through the GSK ShareReward Plan at a price of 1442.655 pence per Ordinary Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly reports the following share acquisitions:
- Sir Andrew Witty: 8 shares (personal) + 8 shares (matching)
- Mr R G Connor: 8 shares (personal) + 8 shares (matching)
- Mr S Dingemans: 8 shares (personal) + 8 shares (matching)
- Mr N Hirons: 8 shares (personal) + 8 shares (matching)
- Mr D S Redfern: 8 shares (personal) + 8 shares (matching)
- Ms C Thomas: 8 shares (personal) + 8 shares (matching)
- Mr P C Thomson: 9 shares (personal) + 9 shares (matching)
- Dr P J T Vallance: 9 shares (personal) + 9 shares (matching)
- Ms E Walmsley: 8 shares (personal) + 8 shares (matching)
- Mrs V A Whyte: 8 shares (personal) + 8 shares (matching)
Investor Verification Checklist
- Verify the total number of shares acquired by each Director/PDMR under the ShareReward Plan.
- Confirm the transaction date (August 11, 2015) and the share price (1442.655 pence).
- Review the company's annual report (Form 20-F) for comprehensive financial data, as this filing does not contain financial metrics.